Interesting point made by TK in the Insidemarket interview (thanks mpk1980). By using ResappDX as a triage tool for patients presenting at the respiratory clinic, the remote assessment reduces the amount of PPE that would otherwise be required for traditional, closer physical assessment (on the basis that all presentations have to be assumed to be possible Covid19 patients). Savings in PPE alone would cover cost of the App (when they start charging), not to mention improved effiicency of staff in the triage process. The PPE savings and increased staff efficiency will see ResappDX rolled out nationally - IMO!
- Forums
- ASX - By Stock
- RAP
- Ann: ResAppDx-EU in Use at COVID-19 Respiratory Clinic
Ann: ResAppDx-EU in Use at COVID-19 Respiratory Clinic, page-103
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online